Apyx Medical Q3 revenue beats estimates, ups FY sales outlook

Apyx Medical

06/11/2025 12:17

Overview

Apyx Medical Q3 revenue grows 12% yr/yr, beating analyst expectations

Adjusted EBITDA loss for Q3 decreased 96%, beating analyst expectations

Outlook

Apyx Medical raises FY2025 revenue guidance to $50.5 mln-$52.5 mln

Surgical Aesthetics revenue expected at $43 mln-$45 mln for FY2025

OEM revenue guidance lowered to $7.5 mln for FY2025

Result Drivers

AYON LAUNCH - Successful commercial launch of AYON Body Contouring System exceeded pre-order expectations, driving revenue growth

SURGICAL AESTHETICS GROWTH - 19% increase in Surgical Aesthetics revenue driven by AYON sales and increased handpiece volume

NEW 510(K) SUBMISSION - Submitted 510(k) for AYON label expansion to include power liposuction, potentially enhancing demand

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$12.88 mln
$12 mln (3 Analysts)
Q3 EPS
-$0.05
Q3 Net Income
-$1.96 mln
Q3 Adjusted EBITDA
Beat
-$91,000
-$2.23 mln (2 Analysts)
Q3 Gross Margin
64.40%
Q3 Income From Operations
-$832,000
Q3 Pretax Profit
-$1.88 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Apyx Medical Corp is $4.00, about 21.5% above its November 5 closing price of $3.14

Press Release: ID:nGNXc5mKPY

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)